JAK inhibitors represent a promising class of disease-modifying therapies for Parkinson's disease, targeting the JAK-STAT signaling pathway that mediates neuroinflammation, microglial activation, and dopaminergic neuron survival. Multiple companies are advancing JAK inhibitors through clinical development, with baricitinib (Eli Lilly) currently in Phase 2 trials for PD. This page serves as an index for all companies developing JAK-STAT pathway-targeted therapies for Parkinson's disease.
The JAK-STAT (Janus kinase–Signal Transducer and Activator of Transcription) pathway is a critical signaling cascade in Parkinson's disease pathophysiology. It is activated by elevated pro-inflammatory cytokines in the substantia nigra and drives neuroinflammation that contributes to dopaminergic neuron loss[1].
Key Molecular Interactions:
Research by Kim et al. (2024) demonstrated that microglial JAK-STAT3 activation is sufficient to drive progressive dopaminergic degeneration in vivo, establishing JAK-STAT as a causal pathway rather than merely a correlate of neuroinflammation[2].
For a detailed mechanistic overview, see JAK-STAT Signaling in Parkinson's Disease.
| Drug | Company | Target | Mechanism | Trial | Status |
|---|---|---|---|---|---|
| Baricitinib | Eli Lilly | JAK1/JAK2 | Direct JAK inhibition | NCT05283460 | Active |
| Baricitinib | Various academic | JAK1/JAK2 | Repurposing | NCT05559177 | Active |
| Drug | Company | Target | Status |
|---|---|---|---|
| Tofacitinib derivatives | Various | JAK1/JAK3 | Discovery |
| Ruxolitinib analogs | In development | JAK1/JAK2 | Preclinical |
| STAT3 inhibitors | Various | STAT3 | Discovery |
Drug: Baricitinib (Olumiant)
Indication: Parkinson's disease
Stage: Phase 2 (NCT05283460)
Background:
Baricitinib is an FDA-approved JAK1/JAK2 inhibitor for rheumatoid arthritis and COVID-19. Eli Lilly and academic collaborators are evaluating baricitinib in Parkinson's disease based on compelling preclinical evidence that JAK-STAT inhibition protects dopaminergic neurons[3].
Mechanism:
Clinical Evidence:
Multiple academic-led trials have investigated baricitinib in PD:
Key Reference: Baricitinib repurposing for Parkinson's disease: a randomized controlled trial (Movement Disorders, 2023)
Related Pages:
Drug: XPro1595
Indication: Parkinson's disease, Alzheimer's disease
Stage: Phase 2 (NCT04472052)
Background:
INmune Bio is developing XPro1595, a dominant-negative TNF inhibitor that acts upstream of the JAK-STAT pathway. By selectively neutralizing soluble TNF-alpha (while preserving membrane-bound TNF), XPro1595 reduces the cytokine signal that activates JAK-STAT signaling in microglia and astrocytes.
Mechanism:
Key Reference: XPro1595 Phase 2 trial in Parkinson's disease (NCT04472052)
Related Pages:
The JAK-STAT pathway can be targeted at multiple nodes:
| Approach | Target Level | Example Drug | Advantages | Disadvantages |
|---|---|---|---|---|
| Cytokine neutralization | Ligand | XPro1595 (anti-TNF) | Selective; preserves some signaling | Does not block all cytokines |
| JAK inhibition | Kinase | Baricitinib, Tofacitinib | Broad suppression of JAK-STAT | Immunosuppression risk; BBB penetration varies |
| STAT3 inhibition | Transcription factor | In development | Direct downstream blockade | Limited BBB-penetrant options |
The JAK-STAT pathway is not merely correlative with neuroinflammation — it is mechanistically involved in driving dopaminergic neuron loss:
Several factors have converged to make JAK inhibitors viable for PD:
JAK/STAT signaling in Parkinson's disease. Trends in Neurosciences. 2019. ↩︎
Microglial JAK-STAT3 activation drives progressive dopaminergic neurodegeneration. Nature Neuroscience. 2024. ↩︎
Targeting JAK/STAT3 signaling for Parkinson's disease therapy. Pharmacological Research. 2023. ↩︎
Baricitinib crosses the blood-brain barrier: implications for JAK inhibitor use in neurodegeneration. Clinical Pharmacokinetics. 2022. ↩︎ ↩︎
Baricitinib repurposing for Parkinson's disease: a randomized controlled trial. Movement Disorders. 2023. ↩︎
JAK-STAT inhibition protects dopaminergic neurons via modulation of neuroinflammation. Cell Death & Disease. 2024. ↩︎
JAK2 inhibition by ruxolitinib reduces neuroinflammation in Parkinson's disease models. Neuropharmacology. 2020. ↩︎